Free public records show Tolmar in 2 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
6 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
2 recalls since 2015 (2 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Markets we cover where free public records show Tolmar: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Tolmar is in.
Stories on the topics Tolmar works in.
Only about a quarter of testosterone booster products had study data showing they raise testosterone. Sexual…
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read